Serina Therapeutics, Inc.
SER · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | -100% | – | 100% | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 87.7% | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,951.5% | – | 19,135.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,960% | – | 19,571.4% |
| EPS Diluted | -0.444 | -0.64 | -0.493 | -0.25 |
| % Growth | 30.7% | -29.7% | -97.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |